BusinessNeuronascent Granted Composition of Matter Patent in Europe for Oral Neuron Regenerative TechnologyBy Nasdaq OMXNov 14, 2017, 12:01 PM UTC
BusinessCognition Therapeutics CEO Kenneth I. Moch to Present at the Stifel 2017 Healthcare ConferenceBy Nasdaq OMXNov 8, 2017, 1:12 PM UTC
BusinessAnavex Life Sciences Presents New Clinical Data of Investigational Alzheimer’s Disease Treatment ANAVEX®2-73 at 2017 Clinical Trials on Alzheimer’s Disease MeetingBy Nasdaq OMXNov 4, 2017, 7:30 PM UTC
BusinessCognition Therapeutics’ Alzheimer’s Disease Candidate CT1812 Meets Phase 1b/2a Study Objectives: Well Tolerated with Positive Influence on Biomarkers of Synapse RecoveryBy Nasdaq OMXNov 4, 2017, 2:45 PM UTC
BusinessCognition Therapeutics to Present Results of CT1812 Phase 1b/2a Clinical Study as Late Breakers at CTAD Meeting on November 2nd and 4thBy Nasdaq OMXOct 30, 2017, 12:12 PM UTC
BusinessCognition Therapeutics Announces Issuance of Broad Composition of Matter Patent for CT1812, a First-in-Class Alzheimer’s Disease Clinical CandidateBy Nasdaq OMXOct 24, 2017, 12:00 PM UTC
BusinessCognition Therapeutics Receives Fast Track Designation from U.S. FDA for First-in-Class Alzheimer’s Candidate, CT1812By Nasdaq OMXOct 16, 2017, 12:00 PM UTC
BusinessAlzheimer’s Foundation of America (AFA) Applauds Issuance of Alzheimer’s Semipostal StampBy Nasdaq OMXOct 6, 2017, 6:36 PM UTC
